Quick Answer
UroGen Pharma Ltd. reported Total Assets of $200.46 million for the year ending 2025.
- UroGen Pharma Ltd. showed a decrease of -29.8% in Total Assets from 2024 to 2025.
- This data is from UroGen Pharma Ltd.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $252.05 million | Q2 2019: $238.57 million | Q3 2019: $226.75 million | Q1 2020: $166.93 million | Q2 2020: $161.08 million | Q3 2020: $139.89 million | Q1 2021: $97.41 million | Q2 2021: $153.77 million | Q3 2021: $134.60 million | Q1 2022: $165.72 million | Q2 2022: $146.14 million | Q3 2022: $128.47 million | Q1 2023: $112.95 million | Q2 2023: $95.36 million | Q3 2023: $193.63 million | Q1 2024: $200.57 million | Q2 2024: $281.85 million | Q3 2024: $301.94 million | Q1 2025: $247.62 million | Q2 2025: $208.72 million | Q3 2025: $185.05 million.
- Over the full 10 years of available data (2016 to 2025), UroGen Pharma Ltd.'s Total Assets has grown by 769.4%.
- Historical annual values: Fiscal year 2025: $200.46 million | Fiscal year 2024: $285.71 million | Fiscal year 2023: $178.31 million | Fiscal year 2022: $135.62 million | Fiscal year 2021: $119.75 million | Fiscal year 2020: $122.01 million | Fiscal year 2019: $202.39 million | Fiscal year 2018: $103.56 million | Fiscal year 2017: $75.55 million | Fiscal year 2016: $23.06 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: